168 results about "Granular leucocyte" patented technology

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

The invention relates to the technical field of biological breeding, in particular to application of an RBX1 gene in cow ovarian granular cells. According to the invention, the RBX1 gene is specifically regulated on the ovarian granulosa cells, and the RBX1 gene is found to have the effect of promoting the proliferation of the granulosa cells; and the gene is provided for the creation of a new high-fecundity breeding material for gene editing cattle in the later period.

The invention discloses a traditional Chinese medicine composition for repairing and / or activating residual ovarian functions of an aging ovary, and a preparation method and application thereof, and relates to the technical field of biology. The traditional Chinese medicine composition is prepared from the following components: radix astragali, radix angelicae sinensis, radix ophiopogonis, radix polygonati officinalis, semen cuscutae, radix morindae officinalis, fructus rubi, rhizoma dioscoreae and folium mori. The invention further provides application of the traditional Chinese medicine composition in repairing and / or activating the residual ovarian function of the senescent ovary and improving the quality of the senescent oocyte, the traditional Chinese medicine composition can increase the volume and weight of the senescent ovary, increase the number of follicles of all levels in the senescent ovary, reduce apoptosis of granular cells in the ovary and improve the survival rate of the senescent ovary. The abnormal rate of oocytes, oxidative stress of the oocytes and DNA damage are reduced, development and maturation of residual follicles are promoted and maintained, and the traditional Chinese medicine composition has a wide application prospect.

The invention provides an ovary-targeting ROS response type SS31 nano-particle and a preparation method and application thereof, and belongs to the field of biomedicine.The ovary-targeting ROS response type SS31 nano-particle is constructed by utilizing a porous metal organic framework to carry hyaluronic acid and utilizing an ROS response type thioketone linker to be combined with mitochondrial targeting peptide SS31, and the ovary-targeting ROS response type SS31 nano-particle is used for preparing the ovary-targeting ROS response type SS31 nano-particle. And the SS31 is targeted and delivered to the ovarian tissue. The nanoparticles target ovary and slowly release SS31 under the action of ROS, so that oxidative stress of oocytes and granular cells caused by female reproductive system diseases such as premature ovarian failure, polycystic ovarian syndrome and the like is reduced, and the mitochondrial function of the oocytes and the granular cells is improved; and a foundation is laid for the subsequent clinical treatment of diseases related to the mitochondrial dysfunction of the female reproductive system by using the SS31.

The invention provides an application of a CTH inhibitor and / or an xCT inhibitor in preparation of a medicine for inhibiting mammal embryo implantation, and relates to the technical field of medicines. The application effect of a cystathionine-gamma-lyase (CTH) inhibitor and / or a solute carrier family 7 member 11 (xCT) inhibitor in inhibition of mammalian embryo implantation is verified through research. The research result shows that the xCT inhibitor and / or the CTH inhibitor can obviously inhibit proliferation of corpus luteinized granular cells and secretion of progesterone of a model mouse; meanwhile, by injecting the xCT inhibitor and / or the CTH inhibitor into the mouse model in vivo, ovary ovulation and the maturation rate of the ovulated oocyte nucleus can be remarkably inhibited, functional corpus luteum formation and embryo implantation can be remarkably reduced, and then a new thought and method are provided for development of contraceptive drugs.

The invention discloses application of amniotic mesenchymal stem cells in preparation of a medicine for improving and / or treating premature ovarian failure. The invention finds that the amniotic mesenchymal stem cells can significantly improve the granular cell proliferation ability and hormone secretion ability, and the premature ovarian failure animal model proves that the amniotic mesenchymal stem cells have leading treatment effects in the aspects of restoring the ovarian functions (hormone secretion, ovary volume and follicle number of each level) of POF mice and improving fertility again. And a foundation is laid for optimizing a treatment strategy of premature ovarian failure and promoting clinical application of mesenchymal stem cell treatment.

The present invention discloses the application of MY-1B in the preparation of drugs for improving ovarian senescence, belonging to the technical field of biomedicine, aiming to solve the problem of how to effectively delay ovarian senescence and improve ovarian function. Experiments have proved that during ovarian senescence, the mRNA m<supgt;5< / supgt;C modification level and the expression level of methyltransferase in ovarian granulosa cells increase. Supplementation with MY-1B can improve the condition caused by mRNA m Nsun2 expression.

The invention belongs to the technical field of biological medicine and livestock breeding, and particularly relates to application of anthocyanin in improving the reproductive function of female beef cattle by adjusting intestinal flora and reducing follicular granule cell apoptosis. Specifically, the invention discovers and verifies for the first time through research that the anthocyanin added into the feed can play roles in regulating the reproductive hormone level of the cattle with the ovarian dysfunction, improving the ovarian function and improving the intestinal flora lineage, and meanwhile, the anthocyanin can resist the apoptosis of ovarian granular cells by resisting oxidative stress injury, so that the reproductive function of the cattle is improved. The invention provides a scientific basis for the application of the anthocyanin in the aspect of improving the reproductive capacity of the female beef cattle, and discloses a mechanism for improving the ovarian function by resisting oxidation and regulating intestinal flora, thereby being beneficial to improving the application prospect of the anthocyanin in animal husbandry, and having a good practical application value.

The invention discloses an antioxidant nano material as well as a preparation method and application thereof, and belongs to the technical field of material preparation. On the basis of the reduction reaction of GSH and selenium-containing substances, oxidation of selenium is effectively protected by utilizing a protective atmosphere, and it is ensured that the selenium element is combined with GSH in a stable valence state. Finally, a novel selenium nano material (GSH-Se) is synthesized, and the GSH-Se has antioxidant ability and GSH-Px-like activity, can relieve oxidative stress induced primary yak follicular granular cell and mouse ovary steroid hormone synthesis disorder, cell apoptosis and mitochondrial division fusion abnormality, and can be used for preparing a novel selenium nano material (GSH-Se). Meanwhile, the GSH-Se can regulate and control steroid hormone synthesis and cell apoptosis of the yak follicular granular cells by inducing mitochondrial fusion, and a new thought is provided for application of the GSH-Se to improvement of female reproductive performance.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for improving ovarian development and a preparation method and application thereof. The reagent for improving ovarian development is prepared by mixing the following raw materials in parts by weight: 20-30 parts of N-acetylcysteine; 5 to 10 parts of tranexamic acid; 3 to 8 parts of creatine; and 3000 parts of water. According to the reagent, the mRNA expression of PKD1P6 and follicle stimulating hormone receptors (FSHR) in ovarian tissues is up-regulated, the activity and functions of cumulus granular cells are enhanced, and apoptosis of the cumulus granular cells is inhibited, so that the effects of effectively promoting follicle development and inhibiting the apoptosis of the cumulus granular cells are achieved.

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

This invention provides the application of CTH inhibitors and / or xCT inhibitors in the preparation of drugs for inhibiting mammalian embryo implantation, relating to the field of pharmaceutical technology. This invention verifies the efficacy of cystathionine-γ-lyase (CTH) inhibitors and / or solute carrier family 7 member 11 (xCT) inhibitors in inhibiting mammalian embryo implantation. The results show that xCT inhibitors and / or CTH inhibitors can significantly inhibit the proliferation of luteinized granulosa cells and progesterone secretion in mouse models. Furthermore, in vivo injection of xCT inhibitors and / or CTH inhibitors into mouse models not only significantly inhibits ovulation and the maturation rate of released oocytes, but also significantly reduces the formation of functional corpus luteum and embryo implantation. Therefore, this application provides new ideas and methods for the development of contraceptive drugs.

The application discloses application of NCOA7 circular RNA nanoliposome in preparation of a drug for treating premature ovarian failure or ovarian reserve function decline, and belongs to the technical field of biological medicine.The present application proves that nuclear receptor coactivator 7 (NCOA7) can relieve ovarian aging and significantly improve the ovarian function and fertility of DOR patients.The present application finds that NCOA7 circular RNA nanoliposome treatment can significantly improve the NCOA7 protein expression level of DOR female ovarian granulosa cells, improve the aging phenotype and growth rate of the DOR female ovarian granulosa cells, and has no significant influence on the biological characteristics of the ovarian granulosa cells, thereby providing a new scheme for rescuing the ovarian function and improving the fertility of DOR women.

The invention provides a novel application of a raspberry extract. It is found through tests that any one of isoquercitrin, ellagic acid, vanillic acid, oleanolic acid, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, tiliroside, tormentic acid and raspberry extract can remarkably improve the activity of the human ovarian granular cells or remarkably improve the oxidative stress level, and the activity of the human ovarian granular cells can be remarkably improved. According to the present invention, the ovarian function can be effectively protected by the eight components, the ovarian function can be effectively protected by the eight components, or the mitochondrial membrane potential level can be significantly regulated and controlled, or the estrogen level in the microenvironment can be effectively maintained, such that the ovarian function can be effectively protected by the eight components, and the raspberry extract containing the eight components. The invention provides a new choice for ovarian function protection products, and also provides a new application for the substances.

The primary culture method of the porcine ovary granular cells comprises the following steps: step 1, taking a fresh porcine ovary, quickly putting the porcine ovary into a Hank's balanced salt solution preheated at 38 DEG C for transportation, repeatedly washing the ovary with the Hank's balanced salt solution to remove blood and impurities, and then extracting follicular fluid with a 5ml syringe under a sterile condition; according to the method, the granular cells can be effectively separated and cultured from the porcine ovary, and the porcine ovary granular cells with higher purity and better activity can be obtained, so that the subsequent cell biology experiment research, such as gene transfection, protein expression analysis and the like, is facilitated; a cell model is provided for researching the physiological functions (such as hormone secretion and follicle development regulation and control) of the porcine ovarian granular cells, the operation is relatively simple, the cost is relatively low, and the used reagents and instruments are common in a cell culture laboratory and are convenient to popularize and apply.

The invention relates to an isolated culture method of functional Chinese softshell turtle ovarian granular cells. The isolated culture method comprises the following steps: S1, collecting ovarian tissues: collecting Chinese softshell turtle ovarian tissues; s2, separating and collecting a granular cell layer; s3, digesting and collecting granular cells; s4, primary culture of granulosa cells: transferring the collected cells into a cell culture bottle containing 4 ml of a complete culture medium for primary culture, wherein the complete culture medium comprises the following main components: a DMEM culture medium, 15% of fetal calf serum, 1% of penicillin streptomycin and 1% of an insulin-transferrin-selenium additive; and S5, subculturing the granular cells. The isolated culture method and the culture medium system provided by the invention are simpler and more time-saving and labor-saving; according to the method, the aromatase CYP19A1 can be expressed normally, the characteristics of the granular cells are kept, the aromatase CYP19A1 can be expressed normally, it is indicated that the in-vitro cultured cells can keep the functionality of the cells, and the in-vitro proliferation capacity of the granular cells is improved to a great extent.

The present application relates to the field of biological medicine and modernization of traditional Chinese medicine, and particularly relates to a therapeutic target, an inhibitor and a traditional Chinese medicine composition for treating ovarian hypofunction caused by oxidative stress and application thereof. The present application first determines SRC tyrosine kinase as a key drug target for preventing and treating the disease. The application of the SRC tyrosine kinase inhibitor (such as secaitinib) in preparing related drugs is provided, which can alleviate the damage of ovarian granulosa cells by inhibiting the SRC activity, down-regulating the expression of antioxidant enzyme related genes and reducing the level of active oxygen. Meanwhile, the present application provides a traditional Chinese medicine composition composed of mulberry, kudzu root, tuckahoe and medlar. The composition can improve the hormone level, enhance the antioxidant capacity, improve the ovarian function and fertility by inhibiting the SRC tyrosine kinase activity and the SRC-RAF1-MEK-ERK signal pathway. The present application provides a new solution for the targeted treatment of ovarian hypofunction and the modernization of traditional Chinese medicine.

The application discloses a kind of marker for predicting oocyte copy number variation and application thereof, the marker includes the combination of CLEC11A, P4HB, EFEMP2, IL32, FTL, FLNA, COL6A3, ACPP and APOO protein.By the marker of the application, the expression level of granulosa cell secretory protein can be determined by granulosa cell transcriptome sequencing, and the genomic CNV condition of corresponding oocyte can be inferred.The detection object of the technical solution is discarded granulosa cell in assisted reproductive technology, so it will not have any impact on oocyte, and it is non-invasive;The present study is a transcriptome and methylation group detection from single cell level, with high-throughput characteristics, and all granulosa cells and oocytes are one-to-one matched, which can reflect the difference between single cell level COCs.

The present invention relates to a medium composition for in vitro fertilization and / or in vitro culture comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and a method using same. The compound or composition suppresses reactive oxygen species and lipid peroxidation in ovarian granulosa cells to preventing cytotoxicity and mitochondrial dysfunction caused by apoptosis and ferroptosis, leading to an improvement in the quality of aged oocytes, and to increase the developmental rate and blastocyst formation rate of pre-implantation embryos, thereby improving the efficiency of in vitro fertilization. In addition, treatment with the medium composition during the vitrification process of in vitro–fertilized embryos improves re-expansion and survival rates, thereby reducing structural and metabolic damage. Accordingly, the present invention can be advantageously applied to an assisted reproductive technology for treating infertility and subfertility, and in vitro fertilization and / or in vitro culture for improving the propagation efficiency of livestock.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to Kunxinning and a preparation method and application thereof. The effective components of the Kunxingning disclosed by the invention are artemisinin and artemisinin. Animal experiments prove that kunxingning can improve the early-onset ovarian insufficiency toxicity state of SD rats caused by tripterygium glycosides, reduce ovarian granular cell apoptosis, improve the ovarian pathological state, promote follicular development, restore the serum sex hormone level to be normal to a certain extent, improve the state of proportion imbalance of Th17 / Treg immune cells, and improve the early-onset ovarian insufficiency toxicity of the SD rats. And the mood cycle of the rats is recovered to a certain extent. Meanwhile, the physiological activity of the tripterygium glycosides composition obtained by compounding the kunxingning and the TG is equivalent to that of the TG.

The invention discloses a method for promoting ovulation of sexual maturity zebrafish by using Gap27, and relates to the technical field of artificial breeding of fish, a gap connecting protein inhibitor Gap27 is applied to ovulation induction of zebrafish, an intercellular communication network in follicles is accurately intervened, the problem of asynchronous ovulation is solved, and in the final stage of maturation of oocytes, ovulation of sexual maturity zebrafish is promoted. Close substance and information exchange is carried out among follicular granule cells through a gap connecting channel formed by connecting protein Cx43, and Gap27 is used as a specific peptide fragment, can simulate an extracellular ring structure of Cx43, and competitively binds with Cx43 on an adjacent cell membrane, so that formation and functions of the gap connecting channel are physically blocked, and the follicular granule cells are separated from each other. When ovarian tissues of sexually mature female fish are exposed in a Gap27 solution, the transmission of inhibitory signals from granular cells to oocytes can be effectively interrupted, the rupture of nuclear membranes of the cells is promoted, and the final maturation process is completed.

The application relates to the field of biological medicine, and particularly discloses application of a sophora japonica extract in preparation of a product for improving the reproductive performance of ewes. The sophora japonica extract can effectively inhibit pyroptosis of ovarian granulosa cells by down-regulating expression of cysteine protease B, further reverses follicle atresia and ovulation disorders caused by pyroptosis, and improves the reproductive performance; animal experiments show that the sophora japonica extract can optimize the follicle development structure of ewes, inhibit overdevelopment of large follicles, and significantly improve the ovulation efficiency, thereby providing a new scheme for inhibiting pyroptosis of ovarian granulosa cells and improving the reproductive performance of livestock.

Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granulosa-like cells by overexpressing transcription factors such as NR5A1 and a RUNX family protein (e.g., RUNXI and / or RUNX2).

The application discloses a doxorubicin scavenger for protecting ovarian fertility and a preparation method thereof, comprising a DNA complex wrapped by a red blood cell membrane, wherein the red blood cell membrane is surface-modified by an anti-Mullerian duct antibody alphaAMH; the doxorubicin scavenger is specifically combined with AMH which is highly expressed in ovarian tissues through alphaAMH, is enriched in the ovarian part in a targeted manner, adsorbs doxorubicin through a DNA fragment in the DNA complex, reduces toxic damage of doxorubicin to ovarian cells, and further protects ovarian fertility. The doxorubicin scavenger can adsorb injected doxorubicin Dox, reduce side effects of doxorubicin Dox on ovarian granulosa cells, and further protect ovarian function and fertility.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

The present application relates to a kind of two-dimensional metal polyphenol complex nanomaterials that can be enriched in ovary, preparation method and application thereof, the nanomaterial can be enriched in ovary, including two-dimensional metal polyphenol complex as substrate, and follicle-stimulating hormone polypeptide grafted to the surface of the substrate;Wherein, the surface of the two-dimensional metal polyphenol complex grafts-COOH functional group and forms 2D MPC-COOH intermediate, the follicle-stimulating hormone polypeptide is covalently grafted with the-COOH on the surface of 2D MPC-COOH intermediate and obtains the two-dimensional metal polyphenol complex nanomaterial.The technical effect of the present application is that the preparation method of nanomaterial is simple, and nanoparticle dispersibility is good, and biosafety is high, and nanomaterial can physically absorb BRD7 target protein through its special structure, block BRD7 into cell nucleus, and then realize the safe down-regulation of KAT7 path and the effective reversal of granulosa cell stress aging.

The application discloses a molecular genetic marker affecting pig sexual maturity and application thereof. The application takes RBP1 as a research object, and adopts molecular and cell biology methods to study the correlation between RBP1 and the initial estrus period. It is found that six SNP sites in the RBP1 promoter region are related to the initial estrus period. Further research shows that the promoter activity of the CC genotype of the g.80408109T>C site is significantly higher than that of the TT genotype, the promoter activity of the AA genotype of the g.80409632A>G site is significantly higher than that of the GG genotype, and it is confirmed that RBP1 can inhibit the ferroptosis of granulosa cells. It can be seen that the mutation in the RBP1 promoter region can affect the expression of RBP1, and RBP1 can accelerate the initial estrus start by inhibiting the ferroptosis of pig ovarian granulosa cells. The application has good application value for the research on ovarian follicle development and initial estrus start.

The invention discloses an ergothioneine composition for improving ovarian vitality and a preparation method and application thereof, the composition comprises D-ribose and ergothioneine, the concentration of the D-ribose in the composition is 5-15 mM, and the concentration of the ergothioneine in the composition is 100-300 [mu] M. The pharmaceutical composition is used for regulating the redox balance of ovarian granular cells, inhibiting inflammatory response and up-regulating anti-mullerian hormone secretion so as to improve the ovarian activity.

This invention discloses a Polygonatum sibiricum vesicle preparation for treating premature ovarian failure, its preparation method, and its application. The preparation method includes: cleaning Polygonatum sibiricum, juicing, filtering to remove residue, and collecting the juice; subjecting the juice to gradient centrifugation to remove residual plant tissue, plant cells, and plant cell debris; then using an extraction reagent for stepwise precipitation, collecting the precipitate, and resuspending it to obtain the final product. The Polygonatum sibiricum vesicle preparation prepared by this invention can be efficiently taken up by ovarian granulosa cells. It effectively treats premature ovarian failure by activating the Nrf2 signaling pathway, upregulating antioxidant enzyme expression, scavenging reactive oxygen species, restoring mitochondrial membrane potential, inhibiting apoptosis, and restoring the expression levels of estrogen, follicle-stimulating hormone, and anti-Müllerian hormone. The preparation method of this invention is standardized, biocompatible, and safe, and has broad clinical application prospects.